Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | ACACB | O00763 | 8/20 | 0.50 |
| ▸ | ACACA | Q13085 | 7/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25080904 | 0.87 | ACACB (0.47) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL14207419 | 0.87 | CKS1B (0.52) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL4288052 | 0.85 | ACACB (0.47) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL4288054 | 0.85 | ACACB (0.47) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL28242347 | 0.84 | DRD2 (0.51) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL28241550 | 0.84 | DRD2 (0.51) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL10230218 | 0.84 | CKS1B (0.59) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL10230212 | 0.84 | CKS1B (0.59) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL14207420 | 0.83 | CKS1B (0.49) | CKS1BSKP1SKP2DRD2ACACB | |
| SCHEMBL4294931 | 0.82 | ALDH1A1 (0.51) | CKS1BSKP1SKP2DRD2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | CKS1B 854/4885SKP1 345/4885SKP2 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.